Changes in albuminuria and the risk of major clinical outcomes in diabetes

Results from ADVANCE-ON

Min Jun, Toshiaki Ohkuma, Sophia Zoungas, Stephen Colagiuri, Giuseppe Mancia, Michel Marre, David Matthews, Neil Poulter, Bryan Williams, Anthony Rodgers, Vlado Perkovic, John Chalmers, Mark Woodward

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

OBJECTIVE To assess the association between 2-year changes in urine albumin-to-creatinine ratio (UACR) and the risk of clinical outcomes in type 2 diabetes. RESEARCH DESIGN AND METHODS We analyzed data from 8,766 participants in the Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation Post-Trial Observational Study (ADVANCE-ON). Change in UACR was calculated from UACR measurements 2 years apart, classified into three groups: Decrease in UACR of ≥30%, minor change, and increase in UACR of ≥30%. By analyzing changes from baseline UACR groups, categorized into thirds, we repeated these analyses accounting for regression to the mean (RtM). The primary outcome was the composite of major macrovascular events, renal events, and all-cause mortality; secondary outcomes were these components. Cox regression models were used to estimate hazard ratios (HRs). RESULTS Over a median follow-up of 7.7 years, 2,191 primary outcomes were observed. Increases in UACR over 2 years independently predicted a greater risk of the primary outcome (HR for ≥30% UACR increase vs. minor change: 1.26; 95% CI 1.13-1.41), whereas a decrease inUACRwas not significantly associatedwith lower risk (HR 0.93; 95% CI 0.83-1.04). However, after allowing for RtM, the effect of "real" decrease in UACR on the primary outcome was found to be significant (HR 0.84; 95% CI 0.75- 0.94), whereas the estimated effect on an increase was unchanged. CONCLUSIONS Changes in UACR predicted changes in the risk of major clinical outcomes and mortality in type 2 diabetes, supporting the prognostic utility of monitoring albuminuria change over time.

Original languageEnglish
Pages (from-to)163-170
Number of pages8
JournalDiabetes Care
Volume41
Issue number1
DOIs
Publication statusPublished - Jan 1 2018

Fingerprint

Albuminuria
Albumins
Creatinine
Urine
perindopril drug combination indapamide
Type 2 Diabetes Mellitus
Odds Ratio
Gliclazide
Mortality
Vascular Diseases
Proportional Hazards Models
Observational Studies
Regression Analysis
Kidney

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Advanced and Specialised Nursing

Cite this

Jun, M., Ohkuma, T., Zoungas, S., Colagiuri, S., Mancia, G., Marre, M., ... Woodward, M. (2018). Changes in albuminuria and the risk of major clinical outcomes in diabetes: Results from ADVANCE-ON. Diabetes Care, 41(1), 163-170. https://doi.org/10.2337/dc17-1467

Changes in albuminuria and the risk of major clinical outcomes in diabetes : Results from ADVANCE-ON. / Jun, Min; Ohkuma, Toshiaki; Zoungas, Sophia; Colagiuri, Stephen; Mancia, Giuseppe; Marre, Michel; Matthews, David; Poulter, Neil; Williams, Bryan; Rodgers, Anthony; Perkovic, Vlado; Chalmers, John; Woodward, Mark.

In: Diabetes Care, Vol. 41, No. 1, 01.01.2018, p. 163-170.

Research output: Contribution to journalArticle

Jun, M, Ohkuma, T, Zoungas, S, Colagiuri, S, Mancia, G, Marre, M, Matthews, D, Poulter, N, Williams, B, Rodgers, A, Perkovic, V, Chalmers, J & Woodward, M 2018, 'Changes in albuminuria and the risk of major clinical outcomes in diabetes: Results from ADVANCE-ON', Diabetes Care, vol. 41, no. 1, pp. 163-170. https://doi.org/10.2337/dc17-1467
Jun, Min ; Ohkuma, Toshiaki ; Zoungas, Sophia ; Colagiuri, Stephen ; Mancia, Giuseppe ; Marre, Michel ; Matthews, David ; Poulter, Neil ; Williams, Bryan ; Rodgers, Anthony ; Perkovic, Vlado ; Chalmers, John ; Woodward, Mark. / Changes in albuminuria and the risk of major clinical outcomes in diabetes : Results from ADVANCE-ON. In: Diabetes Care. 2018 ; Vol. 41, No. 1. pp. 163-170.
@article{1c52f8a6fc114d2092fd0212db48b181,
title = "Changes in albuminuria and the risk of major clinical outcomes in diabetes: Results from ADVANCE-ON",
abstract = "OBJECTIVE To assess the association between 2-year changes in urine albumin-to-creatinine ratio (UACR) and the risk of clinical outcomes in type 2 diabetes. RESEARCH DESIGN AND METHODS We analyzed data from 8,766 participants in the Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation Post-Trial Observational Study (ADVANCE-ON). Change in UACR was calculated from UACR measurements 2 years apart, classified into three groups: Decrease in UACR of ≥30{\%}, minor change, and increase in UACR of ≥30{\%}. By analyzing changes from baseline UACR groups, categorized into thirds, we repeated these analyses accounting for regression to the mean (RtM). The primary outcome was the composite of major macrovascular events, renal events, and all-cause mortality; secondary outcomes were these components. Cox regression models were used to estimate hazard ratios (HRs). RESULTS Over a median follow-up of 7.7 years, 2,191 primary outcomes were observed. Increases in UACR over 2 years independently predicted a greater risk of the primary outcome (HR for ≥30{\%} UACR increase vs. minor change: 1.26; 95{\%} CI 1.13-1.41), whereas a decrease inUACRwas not significantly associatedwith lower risk (HR 0.93; 95{\%} CI 0.83-1.04). However, after allowing for RtM, the effect of {"}real{"} decrease in UACR on the primary outcome was found to be significant (HR 0.84; 95{\%} CI 0.75- 0.94), whereas the estimated effect on an increase was unchanged. CONCLUSIONS Changes in UACR predicted changes in the risk of major clinical outcomes and mortality in type 2 diabetes, supporting the prognostic utility of monitoring albuminuria change over time.",
author = "Min Jun and Toshiaki Ohkuma and Sophia Zoungas and Stephen Colagiuri and Giuseppe Mancia and Michel Marre and David Matthews and Neil Poulter and Bryan Williams and Anthony Rodgers and Vlado Perkovic and John Chalmers and Mark Woodward",
year = "2018",
month = "1",
day = "1",
doi = "10.2337/dc17-1467",
language = "English",
volume = "41",
pages = "163--170",
journal = "Diabetes Care",
issn = "1935-5548",
publisher = "American Diabetes Association Inc.",
number = "1",

}

TY - JOUR

T1 - Changes in albuminuria and the risk of major clinical outcomes in diabetes

T2 - Results from ADVANCE-ON

AU - Jun, Min

AU - Ohkuma, Toshiaki

AU - Zoungas, Sophia

AU - Colagiuri, Stephen

AU - Mancia, Giuseppe

AU - Marre, Michel

AU - Matthews, David

AU - Poulter, Neil

AU - Williams, Bryan

AU - Rodgers, Anthony

AU - Perkovic, Vlado

AU - Chalmers, John

AU - Woodward, Mark

PY - 2018/1/1

Y1 - 2018/1/1

N2 - OBJECTIVE To assess the association between 2-year changes in urine albumin-to-creatinine ratio (UACR) and the risk of clinical outcomes in type 2 diabetes. RESEARCH DESIGN AND METHODS We analyzed data from 8,766 participants in the Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation Post-Trial Observational Study (ADVANCE-ON). Change in UACR was calculated from UACR measurements 2 years apart, classified into three groups: Decrease in UACR of ≥30%, minor change, and increase in UACR of ≥30%. By analyzing changes from baseline UACR groups, categorized into thirds, we repeated these analyses accounting for regression to the mean (RtM). The primary outcome was the composite of major macrovascular events, renal events, and all-cause mortality; secondary outcomes were these components. Cox regression models were used to estimate hazard ratios (HRs). RESULTS Over a median follow-up of 7.7 years, 2,191 primary outcomes were observed. Increases in UACR over 2 years independently predicted a greater risk of the primary outcome (HR for ≥30% UACR increase vs. minor change: 1.26; 95% CI 1.13-1.41), whereas a decrease inUACRwas not significantly associatedwith lower risk (HR 0.93; 95% CI 0.83-1.04). However, after allowing for RtM, the effect of "real" decrease in UACR on the primary outcome was found to be significant (HR 0.84; 95% CI 0.75- 0.94), whereas the estimated effect on an increase was unchanged. CONCLUSIONS Changes in UACR predicted changes in the risk of major clinical outcomes and mortality in type 2 diabetes, supporting the prognostic utility of monitoring albuminuria change over time.

AB - OBJECTIVE To assess the association between 2-year changes in urine albumin-to-creatinine ratio (UACR) and the risk of clinical outcomes in type 2 diabetes. RESEARCH DESIGN AND METHODS We analyzed data from 8,766 participants in the Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation Post-Trial Observational Study (ADVANCE-ON). Change in UACR was calculated from UACR measurements 2 years apart, classified into three groups: Decrease in UACR of ≥30%, minor change, and increase in UACR of ≥30%. By analyzing changes from baseline UACR groups, categorized into thirds, we repeated these analyses accounting for regression to the mean (RtM). The primary outcome was the composite of major macrovascular events, renal events, and all-cause mortality; secondary outcomes were these components. Cox regression models were used to estimate hazard ratios (HRs). RESULTS Over a median follow-up of 7.7 years, 2,191 primary outcomes were observed. Increases in UACR over 2 years independently predicted a greater risk of the primary outcome (HR for ≥30% UACR increase vs. minor change: 1.26; 95% CI 1.13-1.41), whereas a decrease inUACRwas not significantly associatedwith lower risk (HR 0.93; 95% CI 0.83-1.04). However, after allowing for RtM, the effect of "real" decrease in UACR on the primary outcome was found to be significant (HR 0.84; 95% CI 0.75- 0.94), whereas the estimated effect on an increase was unchanged. CONCLUSIONS Changes in UACR predicted changes in the risk of major clinical outcomes and mortality in type 2 diabetes, supporting the prognostic utility of monitoring albuminuria change over time.

UR - http://www.scopus.com/inward/record.url?scp=85038956242&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85038956242&partnerID=8YFLogxK

U2 - 10.2337/dc17-1467

DO - 10.2337/dc17-1467

M3 - Article

VL - 41

SP - 163

EP - 170

JO - Diabetes Care

JF - Diabetes Care

SN - 1935-5548

IS - 1

ER -